Revolution Medicines, Inc. announced on December 5, 2024, the closing of its upsized underwritten public offering, generating gross proceeds of $862.5 million. The offering included 16,576,088 shares of common stock at $46.00 per share and pre-funded warrants for 2,173,917 shares at $45.9999 per warrant.
The total shares issued included 2,445,652 shares from the full exercise of the underwriters' option to purchase additional common stock. All shares and pre-funded warrants were offered by Revolution Medicines.
This successful capital raise significantly strengthens the company's financial position, providing substantial funds to support the continued development and expansion of its product pipeline and preparation for potential commercial launches. The completion of this offering ensures a robust financial runway for the company's strategic initiatives.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.